Side by side: size, value over time, results, valuation, margins, growth, debt and shareholder returns, and any of thirty figures charted over the years (up to 6).
Open these as a peer group: up to 12 companies with suggested peers, each company's rank in the group and percentile in its sector and country, saved for you or your team.
US$ billions, as reported in each year's annual results.
Operating income as a share of revenue. US dollars at each year's exchange rate.
| Measure | CareDx, Inc✕ CDNA · #4,672 in the world |
|---|---|
| Profile | |
| Country | 🇺🇸 USA |
| Sector | Healthcare |
| Industry | Diagnostics and Research |
| Founded | 1998 |
| Size | |
| Market cap | $3.4 B |
| Revenue | $380 M |
The largest companies, each against its nearest peers in value from the same industry.
| Fiscal year | CareDx, Inc |
|---|---|
| 2025 | -8.1%SEC |
| 2024 | 12.2%SEC |
| 2023 | -72.5%SEC |
| 2022 | -24.0%SEC |
| 2021 | -10.0%SEC |
| 2020 | -11.7%SEC |
| 2019 | -19.3%SEC |
| 2018 | -20.3%SEC |
| 2017 | -42.0%SEC |
| 2016 | -91.9%SEC |
| 2015 | -42.4%SEC |
| 2014 | 4.6%SEC |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports; Ed. = the company's report (editors); WD = Wikidata, citing the annual report; Cap = value.today market caps. Hover a figure for its period.
| $-21 M |
| Employees | 645 |
|---|
| Valuation | |
|---|---|
| P/E ratio | 26.1× |
| Price to sales | 6.8× |
| Price to book | 11.1× |
| Free cash flow yield | -0.2% |
| Profitability | |
|---|---|
| Operating margin | -8.1% |
| Net margin | -5.6% |
| Return on equity | -6.3% |
| Growth | |
|---|---|
| Revenue growth | 13.8% |
| Revenue growth, 3 years a year | 5.7% |
| Shareholder returns | |
|---|---|
| Shareholder yield | 2.6% |
| Altman Z-score zone | safe |
|---|
| Data as of | Market cap Oct 2026; ratios FY2025 |
|---|
Market caps from exchange data or SEC filings on the date shown (* last known value, no current one); revenue and net income from the latest annual results; ratios worked out from each company's own statements for the fiscal year shown. ▲ marks the best of these companies where higher or lower is better; size and valuation multiples are marked for no one. Definitions: methodology.